SEC Form 4 · accession 0001618835-18-000046
Evofem Biosciences, Inc. · EVFM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas G Lynch
Director
Period of report
Jul 2, 2018
Accepted (ET)
Jul 3, 2018 · 4:56 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001618835
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jul 2, 2018 | M | 75,000 | $0.00 | A | 75,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2 | — | Jul 2, 2018 | A | 75,000 | A | — | — | Common Stock | 75,000 | 75,000 | D |
| Restricted Stock UnitsF1,F2 | — | Jul 2, 2018 | M | 75,000 | D | — | — | Common Stock | 75,000 | 0 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units were granted in consideration for certain consulting services provided to the Issuer in connection with the consulting agreement between Mr. Lynch and the Issuer dated April 1, 2016.
- F2The restricted stock units vested in full on July 2, 2018.
Remarks
The restricted stock units were granted subject to a 90-day lock-up agreement pursuant to an Underwriting Agreement, the form of which was filed with a Registration Statement on Form S-1 as filed with the SEC on May 16, 2018. During the 90-day lock-up period commencing from May 22, 2018, the Reporting Person may not sell any vested shares.